Hudson Bay Capital Management’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-116,700
| Closed | -$4.02M | – | 858 |
|
|
2020
Q3 | $4.02M | Sell |
116,700
-553,300
| -83% | -$11.8M | 0.06% | 265 |
|
|
2020
Q2 | $11.2M | Sell |
670,000
-15,716
| -2% | -$267K | 0.2% | 85 |
|
|
2020
Q1 | $9.89M | Buy |
685,716
+410,716
| +149% | +$10.5M | 0.25% | 75 |
|
|
2019
Q4 | $9.2M | Sell |
275,000
-165,000
| -38% | -$4.61M | 0.21% | 91 |
|
|
2019
Q3 | $9.21M | Sell |
440,000
-10,000
| -2% | -$204K | 0.25% | 80 |
|
|
2019
Q2 | $9.37M | Buy |
450,000
+154,900
| +52% | +$3.19M | 0.22% | 93 |
|
|
2019
Q1 | $6.59M | Buy |
295,100
+50,100
| +20% | +$1.18M | 0.09% | 223 |
|
|
2018
Q4 | $5.86M | Buy |
245,000
+95,000
| +63% | +$2.46M | 0.08% | 242 |
|
|
2018
Q3 | $4.09M | Hold |
150,000
| – | – | 0.05% | 332 |
|
|
2018
Q2 | $4.03M | Sell |
150,000
-10,000
| -6% | -$306K | 0.06% | 337 |
|
|
2018
Q1 | $5.09M | Buy |
160,000
+140,000
| +700% | +$4.93M | 0.11% | 224 |
|
|
2017
Q4 | $756K | Sell |
20,000
-50,000
| -71% | -$1.61M | 0.02% | 412 |
|
|
2017
Q3 | $1.74M | Sell |
70,000
-90,000
| -56% | -$1.94M | 0.04% | 260 |
|
|
2017
Q2 | $3.29M | Buy |
+160,000
| New | +$3.05M | 0.07% | 256 |
|
Hudson Bay Capital Management's AIMT Position: Q4 2020 in Review
Hudson Bay Capital Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 116,700 shares — an estimated $4.02M sold.
Hudson Bay Capital Management first reported a position in AIMT in Q2 2017 and held it in 14 quarters. The position peaked at $11.2M in Q2 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Hudson Bay Capital Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Hudson Bay Capital Management sold 116,700 Aimmune Therapeutics shares in Q4 2020, an estimated $4.02M.
- Hudson Bay Capital Management first reported a position in Aimmune Therapeutics in Q2 2017 and held it in 14 quarters.
- Hudson Bay Capital Management's Aimmune Therapeutics position peaked at $11.2M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Hudson Bay Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.